These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27123138)

  • 1. Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience.
    Ly KI; Crew LL; Graham CA; Mrugala MM
    Oncol Lett; 2016 May; 11(5):3471-3476. PubMed ID: 27123138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
    Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
    Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.
    Holdhoff M; Ambady P; Abdelaziz A; Sarai G; Bonekamp D; Blakeley J; Grossman SA; Ye X
    Neurology; 2014 Jul; 83(3):235-9. PubMed ID: 24928128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
    Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.
    Chamberlain MC; Johnston SK
    Neuro Oncol; 2010 Jul; 12(7):736-44. PubMed ID: 20511181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 cases.
    Liu J; Sun XF; Qian J; Bai XY; Zhu H; Cui QU; Li XY; Chen YD; Wang YM; Liu YB
    Mol Clin Oncol; 2015 Jul; 3(4):949-953. PubMed ID: 26171213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.
    Atilla PA; Atilla E; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Demirer T; Ilhan O; Arslan O; Gurman G; Ozcan M
    Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):13-17. PubMed ID: 28633037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
    Li Q; Ma Y; Lin Z; Ma J; Kang H; Zhang M; Xu H; Chen B
    J Neurooncol; 2023 May; 163(1):39-46. PubMed ID: 35733032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.
    Tatarczuch M; Lewis KL; Gunjur A; Shaw B; Poon LM; Paul E; Ku M; Wong M; Ai S; Beekman A; Ciaccio PRD; Krigstein M; Wight J; Coombes C; Gilbertson M; Tey A; Shortt J; Nagarajan C; Talaulikar D; Hamad N; Ratnasingam S; Ho SJ; Cochrane T; Hawkes EA; Cheah CY; Opat S; Gregory GP
    EJHaem; 2024 Aug; 5(4):709-720. PubMed ID: 39157596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma].
    Pang DW; Chen FL; Guo HG; Jiang XM; Wei XJ; Liu SC; Huang L; Liang ZL; Li WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1175-1180. PubMed ID: 34362499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.
    Birnbaum T; Stadler EA; von Baumgarten L; Straube A
    J Neurooncol; 2012 Sep; 109(2):285-91. PubMed ID: 22570142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
    Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
    J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose methotrexate dosing strategy in primary central nervous system lymphoma.
    Wang A; Cirrone F; De Los Reyes FA; Papadopoulos J; Saint Fleur-Lominy S; Xiang E
    Leuk Lymphoma; 2022 Jun; 63(6):1348-1355. PubMed ID: 35120432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.
    Cobert J; Hochberg E; Woldenberg N; Hochberg F
    J Neurooncol; 2010 Jul; 98(3):385-93. PubMed ID: 20020180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
    Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
    Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.